Abstract: The present invention relates to a method for treating skin afflictions in a subject comprising a step of administering said subject with a therapeutically effective amount of small extracellular vesicles (sEV) comprising CD98hc. Inventors have demonstrated that healthy dermal fibroblasts produced and secreted EVs bearing characteristic of exosome-like small EVs (sEVs). They have shown that CD98hc was present at the surface of sEVs, transferred and stabilized at the plasma membrane of recipient cells. They observed that the transferred protein was functional both in vitro and in vivo. Furthermore, injection of sEVs in epidermal CD98hc KO mice exhibiting wound healing defect rescued wound closure in vivo. Thus, their findings reveal that CD98hc contained in EVs could potentially be used in vivo to treat and improve multiple skin afflictions by allowing protein rescue.

Abstract: A distributed optical fiber sensor of dynamic stress state comprises: an optical assembly configured to generate a series of optical pulses; an optical fiber of optical length L; an optical system configured to: inject through the first end at least the series of optical pulses; receive at the level of the end at least one series of output optical pulses, arising from the input pulses after propagation and retro-propagation in the fiber; generate at least one continuous reference beam or reference optical pulses on the basis of the optical assembly or of output optical pulses; produce a series of interference zones corresponding to the interference between the reference beam or a reference pulse and a signal optical pulse arising from an output optical pulse; a holographic detector comprising: a liquid-crystal light valve, the valve disposed so that it at least partially covers the interference zones, and producing holograms on the basis of the interference zones; at least one optical detector configured to d

Abstract: The present invention relates to methods and pharmaceutical compositions useful for the treatment of hyperglycemia. Thorough multiple analyses, inventors demonstrated that Gfi1 is expressed in pancreatic acinar cells, starting from the first stages of pancreatic embryonic development. Furthermore, they observed that Gfi1 mRNA levels remain steady throughout embryonic development, while they significantly increase during the first days of life. They challenged conditional mutant mice with high fat diet for 5 months and monitored their weight and glycemia weekly. All the animals displayed a rapid increase in body mass as expected. While control mice rapidly developed a massive hyperglycemia, mutant mice remained normoglycemic throughout the entire experiment. A similar protection from induced diabetes was observed upon treatment with a high dose of Streptozotocin.

Abstract: The present invention relates to a method for improving an industrial yeast strain of industrial interest, particularly a sterile hybrid strain, without resorting to recombinant DNA techniques.

Abstract: The present invention relates to compound of general formula (I) R1 is selected from H, aryl and alkyl, R2 is selected from H, alkyl, aryl and CO—R6; R3 is selected from H, halogen, alkyl, alkenyl, alkynyl, aryl, NHR7, NR7R8, OR7 and SR7; R4 is selected from (C6-C12) alkyl, (C2-C12) alkenyl, (C2-C12) alkynyl and (C6-C10) aryl, R5 represents H, R6, aryl, OH, OR6, O-aryl, SH, SR6, S-aryl, CN, NO2, CF3, COOR6, SO2NR6R7, CONR6R7, NH2, NHR6, NH-aryl, NR6R7, NHCOR6 or aminoacyl; R6 is alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di(alkyl); R7 and R8 identical or different are H or alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di (alkyl), their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof. The compounds are useful for the treatment of cancers.

Abstract: The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a panicein or a derivative thereof, to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject.

Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.

Abstract: A device for identifying an electrical appliance when it is powered up includes a current detector coupled to an electrical power supply cable of the electrical appliance, for detecting the passage of an electrical current in the cable and generating an electrical signal. A voltage generator converts the electrical signal at the output of the current detector into a direct voltage. An RFID circuit stores identification information, coupled to an antenna suitable for receiving and transmitting signals from and to an RFID reader. The device includes a control circuit coupled to the voltage generator and to the RFID circuit, the control circuit configured for producing a change of impedance of the antenna when the direct voltage is applied, the change of impedance allowing to transmit the identification information to the RFID reader.

Abstract: The invention concerns a compound formed by functionalized micro- or nanoparticles associated covalently with rheology-modifying polymers. The invention is characterized in that the functionalized micro- or nanoparticles are functionalized micro- or nanoparticles of cerium oxide (CeO2) having a nominal diameter of between 1 and 1500 nm. The rheology-adapting or -modifying polymers are selected from among non-associative or associative polymers. The invention is used in skin protection or decontamination.

Abstract: A fiber optic sensor for detecting an excitation in proximity to a fiber optic assembly, the excitation inducing a modulation of the phase of an optical signal propagating in the fiber optic assembly, the sensor comprises: a laser assembly emitting at least one laser beam; a fiber optic assembly; an optical system configured to: inject at least one portion of the laser beam; generate at least one laser signal beam issued from the laser beam injected into and propagated in the fiber assembly; generate at least one reference beam from the laser beam or the signal beam; produce at least one interference zone corresponding to the interference between a portion of the reference beam and a portion of the interference signal beam corresponding to the interference between a portion of the reference beam and a portion of the signal beam; a digital holography assembly comprising: a liquid-crystal spatial light modulator; a video camera configured to receive the interference zone and to transcribe it electrically to the

Abstract: The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.

Abstract: The invention relates to a multilayer superoleophobic and/or superhydrophobic material comprising: ? on the one hand, a first constituent that is a conductive substrate or a substrate that has previously been rendered conductive (1): ? the surface of which is modified by chemical and/or physical treatment (2) and that incorporates a first adhesion-promoting conductive layer (3); ? or that incorporates a first adhesion-promoting conductive layer (3); ? and, on the other hand, at least one other constituent that is a superoleophobic and/or superhydrophobic polymer or copolymer layer (4, 5 or 6) composed of one or more monomers based on an aromatic or heteroaromatic ring substituted by one or more fluorocarbon and/or hydrocarbon chains. It is characterized in that the various constituents of said material comply with an increasing hydrophobicity gradient between the first layer deposited on the conductive substrate or substrate previously rendered conductive (1) and the last layer of said material.

Abstract: The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a panicein or a derivative thereof, to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject.

Abstract: The present invention relates to an in vitro or ex vivo method for producing a population of pancreatic beta-cells, comprising the step of inhibiting the expression or the activity of Arx in a population of pancreatic alpha-cells. The present invention also relates to method for inducing the conversion of pancreatic alpha-cells in pancreatic beta-cells in a patient in need thereof.

Abstract: The present invention relates to antibodies anti-sPLA2-IIA and uses thereof.

Abstract: The present invention relates to compound of general formula (1) wherein R1 represents C6-C10 aryl comprising one or two fused rings, wherein from 2 to 5 carbon atoms may be replaced with a heteroatom selected from O, S and NR6, and eventually substituted with from 5 to 11 substituents selected from R6, halo, CN, NO2, CF3, OCF3, COOR6, OCOR6, SO2NR6R7, CONR6R7, NR6R7, NR6COR7, (CH2)p—NR6R7, (CH2)p—OR6 and (CH2)pSR6, as well as, if appropriate, their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof. The compounds are useful for the treatment of cancers.

Abstract: The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of UCP1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of UCP1.

Abstract: The invention concerns a compound formed by functionalized micro- or nanoparticles associated covalently with rheology-modifying polymers. The invention is characterized in that the functionalized micro- or nanoparticles are functionalized micro- or nanoparticles of cerium oxide (CeO2) having a nominal diameter of between 1 and 1500 nm. The rheology-adapting or -modifying polymers are selected from among non-associative or associative polymers. The invention is used in skin protection or decontamination.

Abstract: The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of UCP1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of UCP1.

Abstract: The invention relates to a multilayer superoleophobic and/or superhydrophobic material comprising: on the one hand, a first constituent that is a conductive substrate or a substrate that has previously been rendered conductive (1): the surface of which is modified by chemical and/or physical treatment (2) and that incorporates a first adhesion-promoting conductive layer (3); or that incorporates a first adhesion-promoting conductive layer (3); and, on the other hand, at least one other constituent that is a superoleophobic and/or superhydrophobic polymer or copolymer layer (4, 5 or 6) composed of one or more monomers based on an aromatic or heteroaromatic ring substituted by one or more fluorocarbon and/or hydrocarbon chains. It is characterized in that the various constituents of said material comply with an increasing hydrophobicity gradient between the first layer deposited on the conductive substrate or substrate previously rendered conductive (1) and the last layer of said material.